Bile Acids: Key Players in Inflammatory Bowel Diseases?

Kriaa, Aïcha; Mariaule, Vincent; Jablaoui, Amin; Rhimi, Soufien; Mkaouar, Héla; Hernandez, Juan; Korkmaz, Brice; Lesner, Adam; Maguin, Emmanuelle; Aghdassi, Ali; Rhimi, Moez

doi:10.3390/cells11050901

Cited by 25 publications

(23 citation statements)

References 74 publications

(100 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, BAAT, which is involved in primary bile acid biosynthesis, taurine and hypotaurine metabolism, biosynthesis of unsaturated fatty acids, peroxisome, and bile secretion pathways, was identified. Bile acids (BAs) play key roles in intestinal metabolism and cell signaling and changes in BAs have also been demonstrated to influence gut homeostasis and contribute to the pathogenesis of IBD [ 137 ]. Several BA receptors have been reported to be involved in the development of colorectal cancer, cholangiocellular carcinoma, or their association with cancer cell lines [ 138 ].…”

Section: Discussionmentioning

confidence: 99%

Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor

Sahoo

Borcherding

Chandra

et al. 2022

Cancers

View full text Add to dashboard Cite

Lipopolysaccharide (LPS) is associated with chronic intestinal inflammation and promotes intestinal cancer progression in the gut. While the interplay between LPS and intestinal immune cells has been well-characterized, little is known about LPS and the intestinal epithelium interactions. In this study, we explored the differential effects of LPS on proliferation and the transcriptome in 3D enteroids/colonoids obtained from dogs with naturally occurring gastrointestinal (GI) diseases including inflammatory bowel disease (IBD) and intestinal mast cell tumor. The study objective was to analyze the LPS-induced modulation of signaling pathways involving the intestinal epithelia and contributing to colorectal cancer development in the context of an inflammatory (IBD) or a tumor microenvironment. While LPS incubation resulted in a pro-cancer gene expression pattern and stimulated proliferation of IBD enteroids and colonoids, downregulation of several cancer-associated genes such as Gpatch4, SLC7A1, ATP13A2, and TEX45 was also observed in tumor enteroids. Genes participating in porphyrin metabolism (CP), nucleocytoplasmic transport (EEF1A1), arachidonic acid, and glutathione metabolism (GPX1) exhibited a similar pattern of altered expression between IBD enteroids and IBD colonoids following LPS stimulation. In contrast, genes involved in anion transport, transcription and translation, apoptotic processes, and regulation of adaptive immune responses showed the opposite expression patterns between IBD enteroids and colonoids following LPS treatment. In brief, the crosstalk between LPS/TLR4 signal transduction pathway and several metabolic pathways such as primary bile acid biosynthesis and secretion, peroxisome, renin–angiotensin system, glutathione metabolism, and arachidonic acid pathways may be important in driving chronic intestinal inflammation and intestinal carcinogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor

Sahoo

Borcherding

Chandra

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In contrast, some studies have reported that bile acid metabolism is involved in the pathophysiology of CD. 9 , 10 , 11 , 12 , 13 , 14 The concentration of bile acids in the bile of CD patients is elevated compared with that in healthy individuals, and the production of 7α‐hydroxy‐4‐cholesterin‐3‐one (C4), a precursor of bile acids, is increased due to the malabsorption of bile acids. 25 In addition, fibroblast growth factor 19 (FGF19), which regulates bile acid synthesis, is decreased in patients with CD.…”

Section: Discussionmentioning

confidence: 99%

“… 6 It has been reported that anion exchange resins, such as cholestyramine and colestimide, improve bile acid diarrhea by adsorbing bile acids in the gastrointestinal tract, 7 and colesevelam has been shown to be effective in the management of bile acid diarrhea in patients with CD. 8 However, it has been suggested that abnormal metabolism of secondary bile acids produced in the intestinal tract promotes an inflammatory response in the intestinal epithelium and exacerbates the pathogenesis of CD 9 , 10 , 11 , 12 , 13 , 14 and that resins inhibit intestinal inflammation. 9 Recently, a secondary bile acid, 3‐oxolithocholic acid (3‐oxoLCA), was reported to inhibit TH17 cells; moreover, TH17 cell activation due to decreased 3‐oxoLCA may be involved in the pathogenesis of CD.…”

Section: Introductionmentioning

confidence: 99%

Usefulness of colestimide for diarrhea in postoperative Crohn's disease

et al. 2022

View full text Add to dashboard Cite

Background and Aim Crohn's disease (CD) often causes intractable diarrhea after intestinal resection. Anion exchange resins have been reported to be effective in patients with bile acid diarrhea after distal ileectomy; furthermore, bile acid metabolism has been implicated in the pathogenesis of CD. Therefore, we aimed to examine the effectiveness of colestimide in the management of postoperative CD, and to compare its impact between patients with and those without ileocecal resection. Methods Postoperative CD patients prescribed colestimide for diarrhea between April 2017 and December 2020 were retrospectively evaluated for changes in the total Crohn's disease activity index (CDAI), each CDAI component including diarrhea frequency/week, albumin, and C‐reactive protein (CRP) was evaluated before and after the administration of colestimide. Furthermore, comprehensive patient and physician assessments were reviewed from medical records during the first outpatient visit as a global clinical judgment after the initiation of colestimide therapy. Results A total of 24 patients were included, of whom 17 had a previous history of ileocecal resection. Significant improvement was noted in CDAI and diarrhea frequency only in the ileocecal resection group (CDAI: 114.5 ± 52.7 and 95.4 ± 34.8, P < 0.05; diarrhea frequency/week 23.8 ± 14.1 and 15.4 ± 11.2, P < 0.05, respectively). There was no significant improvement in other CDAI components, albumin level, or CRP level in either group. In the global clinical judgment, 13 and 4 patients in the ileocecal and non‐ileocecal resection groups, respectively, were judged as “effective,” with an overall efficacy rate of 70.8%. Conclusion Colestimide is effective for diarrhea in patients with postoperative CD, especially after ileocecal resection.

show abstract

“…Previous researches have ascribed these changes to alterations in BAs absorptions, synthesis and bacterial modification ( Li et al, 2021a ). Furthermore, these characteristic alterations of BAs are considered to correlate with the disease severity of IBD ( Duboc et al, 2013 ; Kriaa et al, 2022 ). Recent studies have also provided evidence for the involvement of BAs in IBD-associated autophagy, apoptosis, and inflammasome pathways ( Thomas et al, 2022 ).…”

Section: High Correlation Between Dysbiosis Of Gut Microbiota and Ibdmentioning

confidence: 99%

“…Recent studies have also provided evidence for the involvement of BAs in IBD-associated autophagy, apoptosis, and inflammasome pathways ( Thomas et al, 2022 ). Meanwhile, the interactions of BAs with intestinal epithelial cells and immune cells have also been revealed, further providing novel insights into the gut microbiota-BA-host axis in the pathogenesis of IBD ( Yang et al, 2021 ; Kriaa et al, 2022 ).…”

Section: High Correlation Between Dysbiosis Of Gut Microbiota and Ibdmentioning

confidence: 99%

Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases

Zhang

Feng

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic immune-mediated inflammatory disorder of the gastrointestinal tract that is closely associated with dysbiosis of the intestinal microbiota. Currently, biologic agents are the mainstream therapies for IBD. With the increasing incidence of IBD, limitations of biologic agents have gradually emerged during treatment. Recent studies have indicated that gut microbiota is highly correlated with the efficacy of biologic agents. This review focuses on alterations in both the components and metabolites of gut microbiota during biological therapy for IBD, systematically summarises the specific gut microbiota closely related to the clinical efficacy, and compares current predictive models for the efficacy of biologics, further highlighting the predictive value of intestinal microbiota. Based on the mechanistic analysis of faecal microbiota transplantation (FMT) and biologic agents, a new therapeutic strategy, comprising a combination of FMT and biologics, has been proposed as a promising treatment for IBD with improved efficacy.

show abstract

Bile Acids: Key Players in Inflammatory Bowel Diseases?

Cited by 25 publications

References 74 publications

Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor

Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor

Usefulness of colestimide for diarrhea in postoperative Crohn's disease

Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases

Contact Info

Product

Resources

About